Genevoyager has successfully completed the delivery of a number of projects, some of the data are shown below.

● High Safety Profile (data are from 50L GMP lots)

The One-Bac 4.0-derived AAVs present low levels of impurities and are free of rcAAV. 

● High Yields (data are from 50L GMP lots)

The One-Bac 4.0-derived AAVs maintain high yields both before and after purification at a production scale of 50L.

● High Full Capsid Ratio

The One-Bac 4.0 system achieves an impressive full capsid ratio of over 90% in its final product.

● High Infectious Activity

Results from cell and animal experiments demonstrate that One-Bac 4.0-derived AAV exhibits equivalent or higher infectivity compared to HEK293 AAV.

● High Passage Stability of BEV

The Baculovirus Expression Vector (BEV) employed in the One-Bac 4.0 system maintains high stability for multiple passages, ensuring consistent high yield and infectious activity of AAV batches during large-scale production.

● Improved Accessibility

The One-Bac 4.0 system offers a more cost-effective approach to AAV production by replacing costly GMP plasmids and transfection reagents with a streamlined process for baculovirus vector production, significantly reducing the cost of materials for AAV vector manufacturing.

● Reduced timelines

The establishment of a virus seed bank facilitates a rapid and simplified process for viral infection during production. This feature becomes more prominent as the scale of virus production increases, resulting in reduced timelines for production and delivery.